Abstract
Background:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and continuous glucose monitors (CGMs) can each improve glycemic control. This retrospective cohort study evaluates the effect of a CGM in patients with type 2 diabetes (T2D) already receiving GLP-1 RAs.
Methods:
This study analyzed IQVIA’s US medical and pharmacy claims data between January 2019 and December 2023. Two distinct cohorts of patients with T2D were included. The first comprised patients initiating a GLP-1 RA (GLP-1 RA cohort). The second comprised patients on a GLP-1 RA who subsequently started using a CGM (GLP-1 RA + CGM cohort). Propensity score matching of clinical and demographic factors was used to control confounding between groups. Changes in glycated hemoglobin (HbA1c) were assessed quarterly over 12 months; mixed-effects logistic regression was used to assess the impact of time and CGM use. A subgroup analysis was performed based on the duration of GLP-1 RA exposure prior to CGM initiation.
Results:
The final matched sample included 13 221 patients. Both cohorts showed HbA1c reduction, but the GLP-1 RA + CGM cohort demonstrated a faster and more substantial decrease. At 12 months, 31% of GLP-1 RA + CGM patients versus 44% of GLP-1 RA-only patients had HbA1c >9%, while 23% versus 20% achieved HbA1c <7%, respectively. Regression modeling confirmed significantly greater odds for HbA1c reduction with CGM use, which held true across subgroups.
Conclusions:
Adding CGM to GLP-1 RA therapy accelerates and enhances glycemic improvement compared with GLP-1 RA alone, regardless of prior GLP-1 RA duration. These findings support combined use to optimize T2D management and reduce time with poor glycemic control.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
